Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

LGC licenses first DNA test for response to schizophrenia treatment from the Institute of Psychiatry, King’s College London

09.11.2005


LGC, Europe’s leading independent analytical laboratory providing advanced chemical, biochemical and forensic analysis, has announced an exclusive agreement with King’s College London to offer the first pharmacogenetic screening service which will predict whether a patient with schizophrenia will respond positively to the antipsychotic drug clozapine. Developed following 13 years of research by Professor Robert Kerwin and Dr Maria Arranz from the Institute of Psychiatry at King’s, the test will help clinicians tailor the management of medication for schizophrenia to the needs of the patient.



Schizophrenia is considered the most chronic, debilitating and costly mental illness and affects between 1-2% of all populations. There is no permanent cure, but symptoms of the illness can be controlled by antipsychotic drugs. However, not all patients benefit from treatment and up to 40% of patients do not show a complete response - this is known as Treatment Resistant Schizophrenia (TRS).

Although clozapine is the only licensed drug with proven efficiency in the treatment of TRS its treatment can cause potentially serious side effects. It is therefore commonly only prescribed to patients when other medicines have failed. On average patients currently progress through four different antipsychotic medications over a period of five years before being treated with clozapine.


The test, which will be available to the clinical community from early January 2006, is a test based on a panel of single nucleotide polymorphisms (SNPs) that will be analysed using LGC’s proprietary fluorescent HyBeacons DNA probe technology. Dr Paul Debenham, Director of Life Sciences at LGC, said: "This new prediction test of treatment response to clozapine should prove to be an extremely valuable tool for clinicians, aiding them in their prescribing choice of antipsychotic drug for their patients. It will mean that clozapine can be prescribed much earlier on in the treatment of patients who are predicted to be responsive to the drug, thus reducing the suffering time of the patient and the associated cost of care. We are therefore delighted to be in a position to offer this kind of screening service to clinicians for the first time. This agreement is also great news for LGC, enabling us to build on our recent status as the first independent laboratory to become a member of the NHS Genetic Testing Network."

King’s Professor Robert Kerwin said: "This agreement follows 13 years of research at IoP into treatment for schizophrenia, working with more than 200 patients treated with clozapine. We are therefore delighted to be sharing the results of our research and to be working with LGC to be able to bring a viable example of personalised medicine into fruition."

Dr Paul Debenham and Professor Kerwin will be giving a presentation to discuss this new screening service at the ’Good Practice in Biological Investigation’ conference at Institute of Psychiatry, Denmark Hill campus, King’s College London, on Tuesday 8 November 2005. genetic services.

Wendy Taylor | alfa
Further information:
http://www.lgc.co.uk

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

Im Focus: Newly proposed reference datasets improve weather satellite data quality

UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration

"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...

Im Focus: Repairing defects in fiber-reinforced plastics more efficiently

Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.

Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Solar Collectors from Ultra-High Performance Concrete Combine Energy Efficiency and Aesthetics

16.01.2017 | Trade Fair News

3D scans for the automotive industry

16.01.2017 | Automotive Engineering

Nanoparticle Exposure Can Awaken Dormant Viruses in the Lungs

16.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>